BIOGEN IDEC INC. : Biogen Idec's Commitment to MS Demonstrated Through ... 4-traders Key scientific highlights being presented during ECTRIMS from the company's pipeline will include analyses of pooled data from the Phase 3 DEFINE and CONFIRM clinical trials of oral dimethyl fumarate (BG-12), primary results from the daclizumab ... |
